RARE (STOCKS)
Ultragenyx Pharmaceutical Inc.
$23.630000
+0.330000 (+1.42%)
Prev close: $23.300000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Emil D. Kakkis
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,283.36M
- Employees
- 1,294
- P/E (TTM)
- -4.05
- P/B (TTM)
- -28.47
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $673.00M |
| Benefits Costs and Expenses | $1.24B |
| Costs And Expenses | $1.24B |
| Operating Expenses | $1.21B |
| Selling, General, and Administrative Expenses | $349.00M |
| Research and Development | $750.00M |
| Other Operating Expenses | $109.00M |
| Operating Income/Loss | -$535.00M |
| Income/Loss From Continuing Operations After Tax | -$575.00M |
| Income/Loss From Continuing Operations Before Tax | -$571.00M |
| Income Tax Expense/Benefit | $4.00M |
| Income Tax Expense/Benefit, Current | $4.00M |
| Net Income/Loss | -$575.00M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$575.00M |
| Net Income/Loss Available To Common Stockholders, Basic | -$575.00M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$5.83 |
| Diluted Earnings Per Share | -$5.83 |
| Basic Average Shares | 98,600,000 |
| Diluted Average Shares | 98,600,000 |
| Assets | $1.53B |
| Current Assets | $951.00M |
| Inventory | $52.00M |
| Other Current Assets | $899.00M |
| Noncurrent Assets | $581.00M |
| Fixed Assets | $244.00M |
| Intangible Assets | $176.00M |
| Other Non-current Assets | $161.00M |
| Liabilities | $1.61B |
| Current Liabilities | $384.00M |
| Accounts Payable | $31.00M |
| Wages | $89.00M |
| Other Current Liabilities | $264.00M |
| Noncurrent Liabilities | $1.22B |
| Equity | -$80.00M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$80.00M |
| Temporary Equity | $7.00M |
| Liabilities And Equity | $1.53B |
| Net Cash Flow From Operating Activities | -$466.00M |
| Net Cash Flow From Operating Activities, Continuing | -$466.00M |
| Net Cash Flow From Investing Activities | $236.00M |
| Net Cash Flow From Investing Activities, Continuing | $236.00M |
| Net Cash Flow From Financing Activities | $478.00M |
| Net Cash Flow From Financing Activities, Continuing | $478.00M |
| Net Cash Flow | $248.00M |
| Net Cash Flow, Continuing | $248.00M |
| Comprehensive Income/Loss | -$573.00M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$573.00M |
| Other Comprehensive Income/Loss | $2.00M |